[The clinical efficacy of Vuglesorb enterosorbent in diabetic patients].
Carbonic fibrous enterosorbent "Vuglesorb" used as a part of complex anti-diabetic treatment contributes to normalization of metabolism, promotes liquidation of ketoacidosis and principal morbid manifestations. Alongside with this, glycaemia and fructosamine blood level come to the norm. Marked anti-atherogenic effect was also observed. The drug is recommended for the treatment of patients with diabetes mellitus.
Bodnar
P M
PM
Ian'zhon'
V
V
Prystupiuk
O M
OM
Lopushenko
N I
NI
D002244:Carbon / Q000008:administration & dosage*; D003131:Combined Modality Therapy; D003922:Diabetes Mellitus, Type 1 / Q000097:blood / Q000628:therapy*; D003924:Diabetes Mellitus, Type 2 / Q000097:blood / Q000628:therapy*; D004341:Drug Evaluation; D016061:Enterosorption / Q000379:methods*; D006801:Humans; D011208:Powders; D012074:Remission Induction; D013607:Tablets
C025769:Carbosorb; D011208:Powders; D013607:Tablets; D002244:Carbon
Klinichna efektyvnist' enterosorbenta "Vuhlesorb" u khvorykh na tsukrovyĭ diabet.